The abstract is read at the publisher; the summary is JClub's.
In 48 pretreated patients with metastatic KRAS G12D-mutant pancreatic ductal adenocarcinoma, HRS-4642 plus adebrelimab showed a 43.2% confirmed objective response rate at RP2D.
- Why it matters: KRAS G12D-mutant PDAC is linked to an immunosuppressive tumor microenvironment, and effective chemotherapy-free options for refractory disease remain limited.
- What they did: This phase 1/2 NCT06427239 trial used dose escalation to define the recommended phase 2 dose, combining the selective KRAS G12D inhibitor HRS-4642 with PD-L1 blockade adebrelimab.
- The result: At RP2D (n = 37), disease control was 81.1%, median progression-free survival was 5.7 months, and median overall survival was 11.5 months, with no dose-limiting toxicities.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.